Biohaven Pharmaceuticals will seek FDA approval of a new fast-acting nasal spray for migraine, after the drug soared through a Phase 3 clinical trial.
The drug, zavegepant, is a follow-up to Biohaven’s migraine pill Nurtec ODT, which won FDA approval in 2020. Like Nurtec, it’s part of a new class of migraine treatments that target the brain chemical CGRP (calcitonin gene-related peptide).